Welcome to our dedicated page for NextPlat news (Ticker: NXPL), a resource for investors and traders seeking the latest updates and insights on NextPlat stock.
NextPlat Corp reports developments across a healthcare and e-commerce business that provides healthcare and technology solutions through retail and online channels. Recurring news includes financial results, margin and expense updates, 340B covered-entity activity, contracted healthcare services, and prescription fulfillment through its PharmcoRx subsidiary.
Company updates also cover e-commerce and communications products, including voice, data, tracking, and satellite-enabled IoT offerings through Global Telesat Communications. Other recurring themes include AI-enabled pharmacy processing tools, customer and contract activity, Nasdaq listing compliance, and capital-structure actions such as share adjustments and warrant-related disclosures.
NextPlat (NASDAQ:NXPL) reported Q1 2026 revenue of approximately $9.9 million, down 29% from $13.9 million, with a record consolidated gross margin of about 35% versus 21% a year ago.
Healthcare and e-commerce margins improved, operating expenses fell 9% to $4.5 million, and net loss narrowed 42% to $1.1 million. The company ended the quarter with roughly $11 million in cash, $14.2 million in working capital, and no unsecured debt. Growth initiatives include a nationwide healthcare fulfillment partnership, new 340B entities starting July 2026, and an $820,000 NATO-related IoT contract supporting a government and military sales pipeline above $1.2 million.
NextPlat (NASDAQ: NXPL) will release first quarter 2026 financial results for the period ended March 31, 2026 on Thursday, May 14, 2026. A management conference call is scheduled for 8:30 a.m. Eastern that day with CEO David Phipps, CFO Amanda Ferrio and VP Birute Norkute.
Investors should submit questions by May 12, 2026 to investors@nextplat.com. The call has toll-free and international dial-in numbers and a live webcast at https://app.webinar.net/aK21yzvyep9. A replay will be available through May 21, 2026.
NextPlat (NASDAQ: NXPL) expects consolidated Q1 2026 gross margins >34%, driven by a shift to higher‑margin contracted healthcare services. The company forecasts Q1 Healthcare Operations revenue of about $6.7M (down from $9.6M in Q4 2025), an ~9% reduction in operating expenses, and targets positive operating income in Q3 2026. Cash of approximately $11M and working capital of about $14.3M were reported as of March 31, 2026.
NextPlat (NASDAQ: NXPL) announced it has regained compliance with Nasdaq's minimum bid price rule, Listing Rule 5550(a)(2), after Nasdaq confirmed the closing bid was at least $1.00 per share for 10 consecutive business days from April 13, 2026 to April 24, 2026.
Nasdaq sent a compliance letter dated April 27, 2026 and the matter is now closed; NextPlat remains listed on The Nasdaq Capital Market under the ticker NXPL.
NextPlat (NASDAQ: NXPL) said its PharmcoRx subsidiary has deployed AI-powered prescription in-take and processing technology into its pharmacy management system effective April 16, 2026. The tools automate data entry, faxing and refill management, create HIPAA-compliant digital workflows and support scaled fulfillment for new contracted clients.
NextPlat (NASDAQ: NXPL) said its Global Telesat Communications subsidiary received new satellite-enabled IoT orders of approximately $400,000, supporting a military end-user in Eastern Europe and a new customer in Asia. The orders follow a prior $820,000 contract for a NATO military customer.
Through Q1 2026, GTC's government and military IoT product orders totalled more than $1.2 million, which the company cites as momentum for 2026 growth alongside healthcare expansion.
NextPlat (NASDAQ: NXPL) announced a 1-for-10 reverse stock split effective at 12:01 AM ET on April 13, 2026. Every ten pre-split shares will be consolidated into one post-split share, reducing outstanding shares from approximately 26.9 million to approximately 2.7 million.
The company's common stock will open for trading on The Nasdaq Global Market on April 13, 2026 on a post-split basis under the existing ticker NXPL and a new CUSIP 68557F 308. Fractional shares will be settled for cash in lieu; authorized shares remain at 50 million and par value stays at $0.0001.
NextPlat (NASDAQ: NXPL) reported consolidated revenue of $54.3 million for 2025, down 18% year-over-year, driven by lower prescription volume. Healthcare revenue was $39.7 million and e-commerce revenue was $14.6 million. Gross margin declined to ~20% from 26% in 2024.
Operating expenses fell ~50% to $19.9 million; net loss attributable to common stockholders was $11.7 million or ($0.44) per diluted share. The company ended 2025 with ~$13.7 million cash, no meaningful unsecured debt, and ~$15.0 million working capital, and said cost-cutting and 340B/fulfillment focus will support 2026 profitability.
NextPlat (NASDAQ: NXPL) announced a 1-for-10 reverse stock split effective 12:01 a.m. ET on April 6, 2026, with split-adjusted trading to begin on Nasdaq on April 7, 2026 under the existing ticker NXPL.
The split will reduce outstanding shares from 27,026,215 to approximately 2,702,621, cashed-out fractional shares, will not reduce authorized shares, and aims to regain compliance with Nasdaq's minimum bid price requirement.
NextPlat (NASDAQ: NXPL) announced a collaboration with HealthWarehouse to enable nationwide prescription and OTC fulfillment to all 50 U.S. states, expanding PharmcoRx beyond Florida.
The agreement leverages HealthWarehouse's NABP‑accredited digital pharmacy and national fulfillment to support rapid e-commerce expansion and revenue growth in 2026.